Open AccessThe Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib
Author(s) -
Huaqi Wang,
Zhiwei Wang,
Zhenyu Hou,
Xiaohang Yang,
Keyun Zhu,
Manqing Cao,
Xiaolin Zhu,
Huikai Li,
Ti Zhang
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s311526
Subject(s) - apatinib , medicine , hepatocellular carcinoma , neutrophil to lymphocyte ratio , oncology , gastroenterology , cohort , retrospective cohort study , tyrosine kinase inhibitor , angiogenesis , lymphocyte , cancer
Patients with hepatocellular carcinoma (HCC) who might benefit most from anti-angiogenesis therapy remain unknown. In recent years, neutrophil-to-lymphocyte ratio (NLR), an indicator of inflammatory response, has received particular attention in HCC. Herein, we explored the prognostic value of pre-treatment NLR in individuals with unresectable intermediate and advanced hepatocellular carcinoma treated with apatinib, a second-line angiogenesis inhibitor. The findings of this study would assist in precision medicine and provide clinical decision support.